vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and PURE CYCLE CORP (PCYO). Click either name above to swap in a different company.

IRIDEX CORP is the larger business by last-quarter revenue ($14.7M vs $9.1M, roughly 1.6× PURE CYCLE CORP). On growth, PURE CYCLE CORP posted the faster year-over-year revenue change (58.8% vs -69.7%). Over the past eight quarters, PURE CYCLE CORP's revenue compounded faster (69.0% CAGR vs 11.9%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

Pure Cycles, is a bicycle company based in Los Angeles, California that was founded by Michael Fishman, Jordan Schau, Zachary Schau and Austin Stoffers in 2010, as Pure Fix Cycles.

IRIX vs PCYO — Head-to-Head

Bigger by revenue
IRIX
IRIX
1.6× larger
IRIX
$14.7M
$9.1M
PCYO
Growing faster (revenue YoY)
PCYO
PCYO
+128.6% gap
PCYO
58.8%
-69.7%
IRIX
Faster 2-yr revenue CAGR
PCYO
PCYO
Annualised
PCYO
69.0%
11.9%
IRIX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IRIX
IRIX
PCYO
PCYO
Revenue
$14.7M
$9.1M
Net Profit
$4.6M
Gross Margin
37.2%
68.4%
Operating Margin
48.0%
Net Margin
50.0%
Revenue YoY
-69.7%
58.8%
Net Profit YoY
16.0%
EPS (diluted)
$0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
PCYO
PCYO
Q4 25
$14.7M
$9.1M
Q3 25
$12.5M
$11.2M
Q2 25
$13.6M
$5.1M
Q1 25
$11.9M
$4.0M
Q4 24
$12.7M
$5.8M
Q3 24
$11.6M
$12.6M
Q2 24
$12.6M
$7.6M
Q1 24
$11.8M
$3.2M
Net Profit
IRIX
IRIX
PCYO
PCYO
Q4 25
$4.6M
Q3 25
$-1.6M
$6.1M
Q2 25
$-994.0K
$2.3M
Q1 25
$-1.7M
$809.0K
Q4 24
$-834.0K
$3.9M
Q3 24
$-1.9M
$6.6M
Q2 24
$-2.7M
$2.8M
Q1 24
$-3.5M
$118.0K
Gross Margin
IRIX
IRIX
PCYO
PCYO
Q4 25
37.2%
68.4%
Q3 25
32.1%
67.7%
Q2 25
34.5%
63.4%
Q1 25
42.5%
38.2%
Q4 24
44.0%
63.8%
Q3 24
37.3%
77.8%
Q2 24
40.7%
64.0%
Q1 24
37.9%
55.6%
Operating Margin
IRIX
IRIX
PCYO
PCYO
Q4 25
48.0%
Q3 25
-11.3%
53.1%
Q2 25
-6.9%
26.0%
Q1 25
-1.7%
-33.2%
Q4 24
-3.9%
29.9%
Q3 24
-16.1%
62.0%
Q2 24
-20.9%
40.3%
Q1 24
-28.0%
-11.5%
Net Margin
IRIX
IRIX
PCYO
PCYO
Q4 25
50.0%
Q3 25
-12.6%
54.5%
Q2 25
-7.3%
43.9%
Q1 25
-14.2%
20.3%
Q4 24
-6.6%
68.4%
Q3 24
-16.7%
52.6%
Q2 24
-21.2%
37.2%
Q1 24
-29.5%
3.7%
EPS (diluted)
IRIX
IRIX
PCYO
PCYO
Q4 25
$0.19
Q3 25
$-0.09
$0.26
Q2 25
$-0.06
$0.09
Q1 25
$-0.10
$0.03
Q4 24
$-0.05
$0.16
Q3 24
$-0.12
$0.27
Q2 24
$-0.16
$0.12
Q1 24
$-0.21
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
PCYO
PCYO
Cash + ST InvestmentsLiquidity on hand
$6.0M
$17.1M
Total DebtLower is stronger
$8.0M
Stockholders' EquityBook value
$147.5M
Total Assets
$29.2M
$168.1M
Debt / EquityLower = less leverage
0.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
PCYO
PCYO
Q4 25
$6.0M
$17.1M
Q3 25
$5.6M
$21.9M
Q2 25
$6.8M
$14.4M
Q1 25
$7.2M
$16.5M
Q4 24
$2.4M
$19.0M
Q3 24
$3.9M
$22.1M
Q2 24
$4.1M
$20.5M
Q1 24
$5.4M
$20.6M
Total Debt
IRIX
IRIX
PCYO
PCYO
Q4 25
$8.0M
Q3 25
$6.8M
Q2 25
$6.9M
Q1 25
$6.9M
Q4 24
$1.0M
$6.9M
Q3 24
$1.4M
$6.9M
Q2 24
Q1 24
Stockholders' Equity
IRIX
IRIX
PCYO
PCYO
Q4 25
$147.5M
Q3 25
$4.7M
$142.7M
Q2 25
$6.1M
$136.7M
Q1 25
$852.0K
$134.4M
Q4 24
$2.1M
$133.6M
Q3 24
$2.6M
$129.7M
Q2 24
$4.2M
$123.2M
Q1 24
$6.5M
$120.4M
Total Assets
IRIX
IRIX
PCYO
PCYO
Q4 25
$29.2M
$168.1M
Q3 25
$28.4M
$162.3M
Q2 25
$31.6M
$151.7M
Q1 25
$34.2M
$149.7M
Q4 24
$29.1M
$149.7M
Q3 24
$30.2M
$147.4M
Q2 24
$31.2M
$140.4M
Q1 24
$34.1M
$135.2M
Debt / Equity
IRIX
IRIX
PCYO
PCYO
Q4 25
0.05×
Q3 25
0.05×
Q2 25
0.05×
Q1 25
0.05×
Q4 24
0.48×
0.05×
Q3 24
0.53×
0.05×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
PCYO
PCYO
Operating Cash FlowLast quarter
$-979.0K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-0.21×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
PCYO
PCYO
Q4 25
$-979.0K
Q3 25
$-1.2M
$9.4M
Q2 25
$-397.0K
$-503.0K
Q1 25
$-1.1M
$-1.4M
Q4 24
$-1.2M
$5.7M
Q3 24
$-3.1M
$3.1M
Q2 24
$-1.3M
$892.0K
Q1 24
$-1.6M
$-457.0K
Free Cash Flow
IRIX
IRIX
PCYO
PCYO
Q4 25
Q3 25
$-1.2M
Q2 25
$-410.0K
Q1 25
$-1.2M
Q4 24
$-1.2M
Q3 24
$-3.1M
Q2 24
Q1 24
$-1.7M
FCF Margin
IRIX
IRIX
PCYO
PCYO
Q4 25
Q3 25
-9.4%
Q2 25
-3.0%
Q1 25
-9.8%
Q4 24
-9.8%
Q3 24
-26.5%
Q2 24
Q1 24
-14.0%
Capex Intensity
IRIX
IRIX
PCYO
PCYO
Q4 25
Q3 25
0.1%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
IRIX
IRIX
PCYO
PCYO
Q4 25
-0.21×
Q3 25
1.53×
Q2 25
-0.22×
Q1 25
-1.70×
Q4 24
1.44×
Q3 24
0.47×
Q2 24
0.32×
Q1 24
-3.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IRIX
IRIX

Segment breakdown not available.

PCYO
PCYO

Construction$6.5M71%
Water And Wastewater Resource Development Segment$2.5M27%

Related Comparisons